TAIPEI, Taiwan – July 14, 2025 

As exosomes emerge as the next frontier in drug delivery and diagnostics, the standardization of their development and quality control has become a critical success factor. To meet this challenge, Cell Bio Biotechnology will host the seminar "Accelerating the Exosome Development Timeline: An Integrated Workflow from Process Optimization to Efficient Analysis" at BioAsia 2025 on July 24. The session will feature Dr. Pete Serbedzija, Business Development Manager for Asia Pacific at ChemoMetec, and Duncan Griffiths, CEO of Hyperion Analytical, who will jointly explain how to establish a robust and efficient analytical workflow.

This seminar will address the core pain points of exosome development through two key presentations:

Talk 1: Beyond "Good Enough": Why Precise Cell Counting is the First Step to Successful Cell Product Development Dr. Pete Serbedzija will explain how stable and consistent starting cell quality is the foundation for ensuring batch-to-batch consistency in exosome yield and potency. He will share how to leverage ChemoMetec's gold-standard cell counters to fundamentally stabilize cell culture quality and eliminate the inaccuracies of traditional counting methods, thereby building a solid base for downstream process optimization.

Talk 2: Unlocking Key Quality Attributes of Exosomes: In-depth Characterization and Application of High-Resolution NTA Once CQAs for exosomes are defined, their precise measurement becomes the next hurdle. Duncan Griffiths, CEO of Hyperion Analytical, will provide an in-depth look at high-resolution Nanoparticle Tracking Analysis (NTA). He will demonstrate how this technology provides not just particle size and concentration, but also deeper insights into critical metrics like purity and stability, helping researchers quickly identify optimal purification and production conditions.

"We see many teams spending excessive time on trial-and-error in their exosome process development," stated Glenn Yang, CTO at Cell Bio Biotechnology. "The 'integrated workflow' concept we are introducing connects upstream precision cell counting with downstream high-resolution NTA, creating a data-driven optimization cycle. This can dramatically shorten development timelines, reduce the risk of failure, and help bring Taiwan's innovations to market faster."

Event Details:

• Seminar: Accelerating the Exosome Development Timeline: An Integrated Workflow from Process Optimization to Efficient Analysis

• Speakers:

  • Dr. Pete Serbedzija, Business Development Manager - Asia Pacific, ChemoMetec

  • Duncan Griffiths, CEO, Hyperion Analytical

• Date & Time: Thursday, July 24, 2025, 2:00 PM - 2:50 PM

• Location: Room 505C, TaiNEX 1, Taipei

• Registration: https://forms.gle/RZAsdwQovZo3DohdA

About Cell Bio Biotechnology

Cell Bio Biotechnology is a leading supplier in Taiwan's regenerative medicine and cell research sectors, dedicated to introducing the world's most advanced instruments and technologies. We provide comprehensive solutions for clients from basic research to clinical applications. More than just a distributor, we are a trusted partner, empowering our clients to overcome challenges and drive innovation through professional technical support and expert consulting services.